Inhibitory potency of acetylcholinesterase and amyloid beta(1-42) peptide aggregation to the extracts of enthusiasm reducing herbals

Korean Journal of Pharmacognosy

Volumn 38, Issue 4, 2007, Pages 308-311

  Kwon, Young Ee ^a  

^a Woosuk University   (South Korea)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Amyloid beta(1 42); Gardeniae Fructus; Moutan Radicis Cortex

Indexed keywords

EID: 76649145144     PISSN: 02533073     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Khachaturian Z.S. (1985) Diagnosis of Alzhemier's Disease. Arch. Neurol. 42, 1097.
2. Selkoe D.J. (1999) Translating Cell Biology into Therapeutic Advances in Alzhemier's Disease. Nature, 399, A23-A31.
3. Hollander E, Mohs R.C., Davis K.L. (1986) Cholinergic Approaches to the Treatment of Alzheimer's Disease. Br. Med. Bull. 142, 97.
4. Pietrzik C., Behl C. (2005) Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int. J. Exp. Pathol. 86, 173.
5. Silverberg G.D., Mayo M., Saul T., Carvalho J., McGuire D. (2004) Novel ventriculo-peritoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers. Expert. Rev. Neurother. 4, 97.
6. Cottingham M.G., Voskuil J.L., Vaux D.J. (2003) The intact human acetylcholinesterase C-terminal oligomerization domain is alpha-helical in situ and in isolation, but a shorter fragment forms beta-sheet-rich amyloid fibrils and proto-fibrillar oligomers. Biochemistry, 42, 10863.
7. Prous J., Rabasseda X., Castaner J. (1996) SDZ-ENA-713 Cognition Enhancer Acetylcholinesterase Inhibitor. Drugs Future, 19, 656.
8. Lilienfeld S. (2002) Galantamine-a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 8, 159.
9. Cottingham M.G., Hollinshead M.S., Vaux D.J. (2002) Amyloid fibril formation by a synthetic peptide from a region of human acetylcholinesterase that is homologous to the Alzheimer's amyloid-beta peptide. Biochemistry, 41, 13539.
10. De Ferrari G.V., Canales M.A., Shin I., Weiner L.M., Silman I., Inestrosa N.C. (2001) A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation. Biochemistry, 40, 10447.
11. Kurz A. (1998) The therapeutic potential of tacrine. J. Neural Transm. Suppl. 54, 295.
12. Sugimoto H. (2001) Donepezil hydrochloride: a treatment drug for Alzheimer's disease. Chem. Rec. 1, 63.
13. Jann M.W. (2000) Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy, 20, 1.
14. Zarotsky V., Sramek J.J., Cutler N.R. (2003) Galantamine hydrobromide: an agent for Alzheimer's disease. Am. J. Health Syst. Pharm. 60, 446.
15. Barril X., Orozco M., Luque F.J. (2001) Towards improved acetylcholinesterase inhibitors: a structural and computational approach. Mini. Rev. Med. Chem. 1, 255.
16. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., Klein W.L. (2003) Alzheimer's disease-affected brain: presence of oligomeric A-beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA. 100, 10417.
17. Korean source
18. Korean source